-
Prophylaxis against pcp remains the single most cost-effective intervention in HIV+ patients at risk. But treatment has, in some ways, become a moving target in some patients, as their CD4 count rises and falls with newer HIV therapies, medication side effects, and variable compliance.
-
The Food and Drug Administration (FDA) granted approval, on May 23, 2007, to a generic formulation of zidovudine capsules, 100 mg, manufactured by Cipla Limited, of Mumbai, India.
-
The latest microbicide clinical trials will use antiretroviral therapy (ART), which holds both promise and more challenges for investigators.
-
Microbicide research suffered a setback earlier this year when a phase III clinical trial studying cellulose sulfate to block HIV infection was stopped prematurely because there appeared to be a higher rate of HIV infections among the study group than the control group.
-
FDA recently announced these approvals:
Schwartz Bioscience's Neupro (rotigotine transdermal system), a skin patch designed to treat symptoms of early Parkinson's disease.
-
Studies in the U.S. estimate that adverse drug events account for up to 28% of emergency department visits and 25% of ambulatory care encounters and that up to 70% of these visits are preventable.
-
'Lights camera:' Bill calls for videotaped surgeries; Medical researchers not as unbiased as they think
-
A recent study suggests that emergency medicine patients may not have a high level of acceptance of the practice of providing an exemption to informed consent for research involving emergency medical settings.
-
The Seattle hospital that performed growth attenuation treatments and surgery on the severely disabled child known as "Ashley" took place in violation of Washington state law, but the hospital stands behind the ethics and best-interest issues that resulted in the treatment.
-
"Lessons Learned From the Gulf Coast Hurricanes," recently published by the American Health Lawyers Association, looks at legal issues that arose in the context of the 2005 hurricanes.